logo-loader

Can InterContinental Hotels stop more investors checking out?

Other announcements on Friday include from Avast, Dechra Pharmaceuticals and London Stock Exchange Group

Intercontinental Hotels -

InterContinental Hotels Group PLC (LON:IHG) will deliver a third-quarter update on Friday.

Over the decade to the end of this July, shares in the Holiday Inn owner's shares soared sixfold to an all-time high of above £57, but have fallen 17% in the two and a half months since.

In August's half-year results, the FTSE 100 showed evidence of weaker revenue available per room (revpar) in the key market of the US and China.

Revenues of US$1.01bn in the first six months of 2019 were up 13% on the same period last year but slightly short of the US$1.02bn that analysts expected, with comparable revpar down 0.2% in the second quarter from the 0.3% growth in the first.

Analysts at Morgan Stanley estimate there will be a 0.1% decline in group revpar in the third quarter, compared to 0.1% growth in the first half, based on continued weakness that has been shown in market data in the US and more acutely in Greater China.

"This is despite easy comps, so it implies a slowdown in the two-year growth rate to 0.9% in the quarter, compared to 3.8% in H1."

For the full year MS estimates 0.4% revpar growth, which would require a pick-up in the fourth quarter to 1.7%.

After flat underlying profits in the first half, the analysts said IHG needs 10% growth in the second half to hit consensus expectations of $870mln. 

Significant events on Friday 18 October:

Trading statement: Avast PLC (LON:AVST), Dechra Pharmaceuticals (LON:DPH), InterContinental Hotels Group (LON:IHG), London Stock Exchange Group (LON:LSE)

Economic announcements: European Council meeting

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Revenue guidance from OptiBiotix as it eyes NASDAQ listing

OptiBiotix Health (LON:OPTI) provides a commercial progress update, explaining why in their financials some items are separated. CEO Stephen O'Hara tells Proactive London what's behind his thinking adding that Optibiotix hopes to reach profitability in 2020. News here too on Sweetbiotix and...

1 day, 23 hours ago

RNS

Holding(s) in Company

2 days, 1 hour ago

Director Declaration

5 days, 20 hours ago

Total Voting Rights

2 weeks, 3 days ago

Holding(s) in Company

3 weeks, 6 days ago

Holding(s) in Company

on 12/12/19

Holding(s) in Company

on 10/12/19

Directorate Change

on 6/12/19

Total Voting Rights

on 2/12/19

2 min read